Novartis says safety of new painkiller confirmed in trials

09/29/2004 | Reuters

Novartis reported trials show Prexige causes less heart risk and fewer stomach ulcers than anti-inflammatory drugs. The Swiss company, which considers Prexige a potential blockbuster with possible sales of more than $1 billion, released the trial results to minimize concerns about side effects.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY